SLC25A42‐associated mitochondrial encephalomyopathy: Report of additional founder cases and functional characterization of a novel deletion
Authors:
Open Access
- 4 May 2021
- journal article
- research article
- Published by Wiley in JIMD Reports
- Vol. 60 (1) , 75-87
Abstract
SLC25A42 is the main transporter of coenzyme A (CoA) into mitochondria. To date, 15 individuals have been reported to have one of two bi‐allelic homozygous missense variants in the SLC25A42 as the cause of mitochondrial encephalomyopathy, of which 14 of them were of Saudi origin and share the same founder variant, c.871A > G:p.Asn291Asp. The other subject was of German origin with a variant at canonical splice site, c.380 + 2 T > A. Here, we describe the clinical manifestations and the disease course in additional six Saudi patients from four unrelated consanguineous families. While five patients have the Saudi founder p.Asn291Asp variant, one subject has a novel deletion. Functional analyses on fibroblasts obtained from this patient revealed that the deletion causes significant decrease in mitochondrial oxygen consumption and ATP production compared to healthy individuals. Moreover, extracellular acidification rate revealed significantly reduced glycolysis, glycolytic capacity, and glycolytic reserve as compared to control individuals. There were no changes in the mitochondrial DNA (mtDNA) content of patient fibroblasts. Immunoblotting experiments revealed significantly diminished protein expression due to the deletion. In conclusion, we report additional patients with SLC25A42‐associated mitochondrial encephalomyopathy. Our study expands the molecular spectrum of this condition and provides further evidence of mitochondrial dysfunction as a central cause of pathology. We therefore propose that this disorder should be included in the differential diagnosis of any patient with an unexplained motor and speech delay, recurrent encephalopathy with metabolic acidosis, intermittent or persistent dystonia, lactic acidosis, basal ganglia lesions and, especially, of Arab ethnicity. Finally, deep brain stimulation should be considered in the management of patients with life altering dystonia.Keywords
Funding Information
- King Abdulaziz City for Science and Technology (11‐BIO2221‐20)
- King Faisal Specialist Hospital and Research Centre (2060035, 2120022, 2180004, 2110006)
- University of Kentucky (G0800674)
- Wellcome Trust Centre for Mitochondrial Research (203105/Z/16/Z)
This publication has 35 references indexed in Scilit:
- Rett Syndrome, a Neurodevelopmental Disorder, Whole-Transcriptome, and Mitochondrial Genome Multiomics Analyses Identify Novel Variations and Disease PathwaysOMICS: A Journal of Integrative Biology, 2020
- Genetic and phenotypic characterization of NKX6‐2‐related spastic ataxia and hypomyelinationEuropean Journal of Neurology, 2019
- ISCA2 mutation causes infantile neurodegenerative mitochondrial disorderJournal of Medical Genetics, 2014
- Nonenzymatic Protein Acylation as a Carbon Stress Regulated by Sirtuin DeacylasesMolecular Cell, 2014
- Exome Sequence Reveals Mutations in CoA Synthase as a Cause of Neurodegeneration with Brain Iron AccumulationThe American Journal of Human Genetics, 2014
- Mutations in NALCN Cause an Autosomal-Recessive Syndrome with Severe Hypotonia, Speech Impairment, and Cognitive DelayThe American Journal of Human Genetics, 2013
- OXPHOS gene expression and control in mitochondrial disordersBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009
- Transcriptional co-expression and co-regulation of genes coding for components of the oxidative phosphorylation systemBMC Genomics, 2008
- Fourteen novel human members of mitochondrial solute carrier family 25 (SLC25) widely expressed in the central nervous systemGenomics, 2006
- Mitochondrial DNA mutations in human diseaseNature Reviews Genetics, 2005